Matches in SemOpenAlex for { <https://semopenalex.org/work/W1983801034> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W1983801034 abstract "Patients with good-risk germ cell tumors have an approximately 85-95% chance of cure with standard chemotherapy. However, acute and late toxicity may be severe and negatively influence the quality of life. In an attempt to reduce toxicity, we evaluated a new schedule including bleomycin administered-as a continuous infusion in patients with low and intermediate volume metastatic disease. Patients were treated as follows: cisplatin, 100 mg/m(2) day 4; etoposide, 100 mg/m(2) days 1 through 5; bleomycin, 15 unit bolus on day 1 followed by 30 mg as a continuous infusion for 72 h, with cycles repeated every 21 days. Between 1992 and 1996, 25 patients entered the study and were assessable for response and side effects. Major patient characteristics were: performance status ECOG 0-1; minimal disease, 13 patients, intermediate disease, 12; median age, 33 years (range 15-50). Twenty-one of 25 patients (84%) achieved a complete remission, 2 patients achieved a partial remission, and 2 patients did not respond to the regimen. At a median follow-up of 24 months, 24/25 patients were alive, 23 were without evidence of disease, and I had persistent disease. Grade III/IV side effects included leuko/neutropenia (8 patients), anemia (3 patients), and nausea/vomiting (3 patients). No drug-related deaths were observed, and no evidence of pulmonary toxicity was registered. In conclusion, the PEBi regimen is an effective and well-tolerated regimen in patients with good-risk germ cell tumors and may be considered as a front-line chemotherapy." @default.
- W1983801034 created "2016-06-24" @default.
- W1983801034 creator A5011019639 @default.
- W1983801034 creator A5013722013 @default.
- W1983801034 creator A5023027625 @default.
- W1983801034 creator A5036344172 @default.
- W1983801034 creator A5041800281 @default.
- W1983801034 creator A5045311601 @default.
- W1983801034 creator A5053376791 @default.
- W1983801034 creator A5061056790 @default.
- W1983801034 creator A5064311561 @default.
- W1983801034 date "1997-09-01" @default.
- W1983801034 modified "2023-09-27" @default.
- W1983801034 title "Cisplatin, etoposide and bleomycin infusion (PEBi regimen) in good-risk patients with germ cell tumors" @default.
- W1983801034 doi "https://doi.org/10.3892/or.4.5.913" @default.
- W1983801034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21590165" @default.
- W1983801034 hasPublicationYear "1997" @default.
- W1983801034 type Work @default.
- W1983801034 sameAs 1983801034 @default.
- W1983801034 citedByCount "0" @default.
- W1983801034 crossrefType "journal-article" @default.
- W1983801034 hasAuthorship W1983801034A5011019639 @default.
- W1983801034 hasAuthorship W1983801034A5013722013 @default.
- W1983801034 hasAuthorship W1983801034A5023027625 @default.
- W1983801034 hasAuthorship W1983801034A5036344172 @default.
- W1983801034 hasAuthorship W1983801034A5041800281 @default.
- W1983801034 hasAuthorship W1983801034A5045311601 @default.
- W1983801034 hasAuthorship W1983801034A5053376791 @default.
- W1983801034 hasAuthorship W1983801034A5061056790 @default.
- W1983801034 hasAuthorship W1983801034A5064311561 @default.
- W1983801034 hasConcept C126322002 @default.
- W1983801034 hasConcept C141071460 @default.
- W1983801034 hasConcept C2776694085 @default.
- W1983801034 hasConcept C2776938808 @default.
- W1983801034 hasConcept C2777063308 @default.
- W1983801034 hasConcept C2778119113 @default.
- W1983801034 hasConcept C2778336483 @default.
- W1983801034 hasConcept C2778822529 @default.
- W1983801034 hasConcept C2780580376 @default.
- W1983801034 hasConcept C2780852908 @default.
- W1983801034 hasConcept C2781047374 @default.
- W1983801034 hasConcept C2781413609 @default.
- W1983801034 hasConcept C29730261 @default.
- W1983801034 hasConcept C71924100 @default.
- W1983801034 hasConcept C90924648 @default.
- W1983801034 hasConceptScore W1983801034C126322002 @default.
- W1983801034 hasConceptScore W1983801034C141071460 @default.
- W1983801034 hasConceptScore W1983801034C2776694085 @default.
- W1983801034 hasConceptScore W1983801034C2776938808 @default.
- W1983801034 hasConceptScore W1983801034C2777063308 @default.
- W1983801034 hasConceptScore W1983801034C2778119113 @default.
- W1983801034 hasConceptScore W1983801034C2778336483 @default.
- W1983801034 hasConceptScore W1983801034C2778822529 @default.
- W1983801034 hasConceptScore W1983801034C2780580376 @default.
- W1983801034 hasConceptScore W1983801034C2780852908 @default.
- W1983801034 hasConceptScore W1983801034C2781047374 @default.
- W1983801034 hasConceptScore W1983801034C2781413609 @default.
- W1983801034 hasConceptScore W1983801034C29730261 @default.
- W1983801034 hasConceptScore W1983801034C71924100 @default.
- W1983801034 hasConceptScore W1983801034C90924648 @default.
- W1983801034 hasLocation W19838010341 @default.
- W1983801034 hasLocation W19838010342 @default.
- W1983801034 hasOpenAccess W1983801034 @default.
- W1983801034 hasPrimaryLocation W19838010341 @default.
- W1983801034 isParatext "false" @default.
- W1983801034 isRetracted "false" @default.
- W1983801034 magId "1983801034" @default.
- W1983801034 workType "article" @default.